About Us
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
|
|
|
BMRN - BioMarin Pharmaceuti...| Previous Close | $81.76 | Open | $80.31 |
| Volume | 3.03M | Market Cap | 14.842B |
| Yield | Last Dividend |
| Robert W. Baird Stick to Their Buy Ratin... | 9:27 AM |
| Robert W. Baird Stick to Their Buy Rating for BioMarin Pharmaceutical | |
| Earnings and Growth Analysis : NASDAQ:BM... | 6:51 AM |
| Earnings, Analyst opinion and estimate and latest Covid-19 (Coronavirus) impact on these hot stocks to invest | |
| BIOMARIN INVESTIGATION INITIATED BY FORM... | 02/26/21 |
| NEW ORLEANS, Feb. 26, 2021 /PRNewswire/ -- Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick &... | |
| Phenylketonuria Treatment Market Analysi... | 02/26/21 |
| Global Phenylketonuria Treatment Market Analysis to 2027 is a specialized and in-depth study of the pharmaceutical industry with a special focus on th... | |
| Biomarin Pharma Earnings, Revenue Beat i... | 02/25/21 |
| https://www.investing.com/news/stock-market-news/biomarin-pharma-earnings-revenue-beat-in-q4-2430577 | |
| BioMarin Announces Fourth Quarter and Re... | 02/25/21 |
| SAN RAFAEL, Calif., Feb. 25, 2021 /PRNewswire/ -- Financial Highlights (in millions of U.S. dollars, except per share data, unaudited) Three Months En... | |
| BioMarin to Participate in Four Upcoming... | 02/24/21 |
| SAN RAFAEL, Calif., Feb. 24, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that management will participate in four... | |
| BioMarin Pharmaceutical Does Earnings Su... | 02/23/21 |
| BioMarin Pharmaceutical announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by?... | |
| BioMarin Appoints Former Goldman Sachs P... | 02/18/21 |
| SAN RAFAEL, Calif., Feb. 18, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (Nasdaq:BMRN), a global leader in providing therapies for rare genetic ... | |
| Hunter Syndrome Treatment Market Researc... | 02/15/21 |
| Global Coronavirus pandemic has impacted all industries across the globe, ???Hunter Syndrome Treatment Market??? is no exception. As the global econom... | |
| Healthcare hedge fund Rhenman still buoy... | 02/09/21 |
| Healthcare hedge fund Rhenman still buoyant on sector, as flagship strategy advances in January Submitted By Hugh Leask | 09/02/2021 - 4:32pm The heal... | |
| Critical Survey: BioMarin Pharmaceutical... | 02/06/21 |
| BioMarin Pharmaceutical (NASDAQ:BMRN) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior stock? We will contrast the two ... | |
| Head to Head Survey: BioMarin Pharmaceut... | 02/06/21 |
| BioMarin Pharmaceutical (NASDAQ:BMRN) and Annexon (NASDAQ:ANNX) are both medical companies, but which is the superior stock? We will contrast the two ... | |
| Insider Selling: BioMarin Pharmaceutical... | 02/05/21 |
| BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 8,334 shares of the business???s stock in a transaction dated Friday, Januar... | |
| Cell and Gene Therapy Market 2020 - Amge... | 02/04/21 |
| CMI analyses the Cell and Gene Therapy trends, by country, for a five year review period (2020-2027) forecast period. Our regular clients asked us to ... | |
| BioMarin Pharmaceutical Inc. (NASDAQ:BMR... | 02/01/21 |
| BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) CEO Jean Jacques Bienaime sold 8,333 shares of BioMarin Pharmaceutical stock in a transaction dated Wednesd... | |
| BioMarin Earns Top Marks in Human Rights... | 01/28/21 |
| SAN RAFAEL, Calif., Jan. 28, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced the Company received the top score of 10... | |
| BioMarin to Host Fourth Quarter and Full... | 01/26/21 |
| SAN RAFAEL, Calif., Jan. 26, 2021 /PRNewswire/ -- BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) today announced that Jean-Jacques Bienaim??, Chairman an... | |
| Global Skeletal Complications Treatment ... | 01/25/21 |
| Databridgemarketresearch.com Present ???Skeletal Complications Treatment Market??? Industry Trends and Forecast to 2027??? new report to its research ... | |
| Intel, BioMarin, Avid Technology Stocks ... | 01/18/21 |
| Analysts have picked up the stocks with three companies with renewed price targets, this list includes Intel, BioMarin, Avid Technology. | |
| Why top market analysts back stocks like... | 01/17/21 |
| Intel logo exhibited during the Mobile World Congress, on February 28, 2019 in Barcelona, Spain. Joan Cros | NurPhoto | Getty Images Earnings season i... | |
| FXNEWS24 |Why top market analysts back s... | 01/17/21 |
| Why top market analysts back stocks like Intel, BioMarin | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Forex News | |
| Why high market analysts again shares li... | 01/17/21 |
| East Auto News the news magazine for cars, industry, politics, markets and economy, motorsports and much more | |
| BIOMARIN INVESTIGATION INITIATED by Form... | 01/15/21 |
| NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (?... | |
| Wedbush Stick to Their Buy Rating for Bi... | 01/12/21 |
| Wedbush Stick to Their Buy Rating for BioMarin Pharmaceutical | |
| BioMarin's stock tumbles 6% after sharin... | 01/11/21 |
| Shares of BioMarin Pharmaceuticals Inc. undefined tumbled 6.6% in trading on Monday, the day after the company shared positive findings from a Phase 3... | |
| BioMarin???s One-Year Data on Its Hemoph... | 01/11/21 |
| The company hopes to persuade the FDA to consider approval based on one-year data???instead of requiring two years of follow-up on trial participants. | |
| Covid-19 Impact On Cell and Gene Therapy... | 01/11/21 |
| COHERENT MARKET INSIGHTS has added a new report titled Global Cell and Gene Therapy Market with analysis provides the insights which bring marketplace... | |
| Still reeling from rejection, BioMarin r... | 01/11/21 |
| BioMarin now has the Phase III data it needs to refile valrox, its gene therapy for hemophilia A, at the EMA ??? and possibly convince the FDA to reco... | |
| FXNEWS24 |BioMarin, Alkermes, Ionis: Are... | 01/05/21 |
| BioMarin, Alkermes, Ionis: Are These Health Care Stocks Set To Outperform In 2021? | UK Stocks, Forex, Commodities, Crypto, Live Market News- Daily Fo... | |
| Date | 2021-02-25 (AMC) | Est. (EPS/Rev.) | ($0.19)/ 440.23M |
| Actual (EPS/Rev.) | $0.12/ $452.12 M | EPS (TTM) | 0 |
| Total Revenue | $1.3B | Total Liabilities | $2.1B |
| Cost of Revenue | $2.5B | Total cash flow | $3.2 |
| Total Assets | $29.98B |
| % Insider | 12.52% | % Institutional | 76.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Vanguard | 12.52% (+6.4%) | Bank of America | 10.43% |
| Service Name | Trader | % Success | |
|---|---|---|---|
| Lewis Aung's long pick | Kyaw Aung | 69.00 % | Subscribe |
| Alpha Swing Trades | Jonathan | 68.00 % | Follow |
| Best Trading Ideas | Best Trading Ideas | 54.00 % | Subscribe |
Get winning Stock, Option and Cryptocurrency trade ideas from pro-traders. Follow their strategies, see how they perform.
We are not a registered investment advisor. All investments involve risk, individual's trading does not guarantee future results or returns. Investors are fully responsible for any investment decisions they make. References to specific securities should not be construed as a recommendation to buy or sell that security only mentioned for informational purposes.
